Large B-Cell Lymphoma (LBCL) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting large b-cell lymphoma (lbcl) clinical trials across 21 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Bologna, Italy, Chicago, Illinois, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Large B-Cell Lymphoma (LBCL) Trials at a Glance

7 actively recruiting trials for large b-cell lymphoma (lbcl) are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Bologna, Chicago, and Barcelona. Lead sponsors running large b-cell lymphoma (lbcl) studies include Beijing Tongren Hospital, Kite, A Gilead Company, and AstraZeneca.

Browse large b-cell lymphoma (lbcl) trials by phase

Treatments under study

About Large B-Cell Lymphoma (LBCL) Clinical Trials

Looking for clinical trials for Large B-Cell Lymphoma (LBCL)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Large B-Cell Lymphoma (LBCL) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Large B-Cell Lymphoma (LBCL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

Large B-Cell Lymphoma (LBCL)
Ruijin Hospital30 enrolled1 locationNCT07514169
Recruiting
Phase 1

Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

Large B-Cell Lymphoma (LBCL)
Tel-Aviv Sourasky Medical Center12 enrolled1 locationNCT07361224
Recruiting

Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
N.N. Alexandrov National Cancer Centre76 enrolled1 locationNCT07524816
Recruiting
Phase 2

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
Zhejiang University40 enrolled1 locationNCT04661020
Recruiting
Phase 2

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital100 enrolled1 locationNCT07461831
Recruiting
Phase 3

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 2

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793